Bolt Biotherapeutics (BOLT) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$4.7M

Revenue (quarter)

$5,000.00

Revenue growth (year over year)

−99.72%

Gross profit (trailing twelve months)

$4.7M

Gross margin

100.00%

Net income (trailing twelve months)

−$28.7M

Net income (quarter)

−$7.7M

Net income growth (year over year)

+9.82%

Net margin

−611.47%

Return on equity

−111.65%

EPS (trailing twelve months)

−$16.51

Book value per share

$6.56

P/E (trailing twelve months)

—

Price to book

0.65

Debt to assets

68.67%

Payout ratio

—

Dividend yield

—

Company profile

Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.

• Is Bolt Biotherapeutics (BOLT) profitable?

  No. Bolt Biotherapeutics reported a net loss of $28.7M over the trailing twelve months.

• How much revenue does Bolt Biotherapeutics (BOLT) make?

  Bolt Biotherapeutics generated $4.7M in revenue over the trailing twelve months, down 99.72% year over year.

• How do I buy stock in Bolt Biotherapeutics (BOLT)?

  BOLT trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.